Skip to search formSkip to main contentSkip to account menu

SB 207499

Known as: SB-207499 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2007
Review
2007
Phosphodiesterase-4 (PDE4) is an important cAMP-metabolising enzyme in immune and inflammatory cells, airway smooth muscle and… 
Highly Cited
2002
Highly Cited
2002
In an attempt to elaborate in vitro on a therapeutic strategy that counteracts an inflammatory signal, we previously reported a… 
2002
2002
Background. Recent advances in the understanding of immunomodulatory properties of phosphodiesterase 4 (PDE4) inhibitors… 
Review
2001
Review
2001
  • M. Giembycz
  • Expert Opinion on Investigational Drugs
  • 2001
  • Corpus ID: 21654297
Cilomilast (Ariflo™ , SB-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective… 
Highly Cited
2000
Highly Cited
2000
The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP… 
2000
2000
  • T. Torphy
  • IDrugs : the investigational drugs journal
  • 2000
  • Corpus ID: 30380859
This meeting underscored advances in the exploitation of cyclic nucleotide phosphodiesterases (PDEs) as drug targets. One… 
Review
1999
Review
1999
Cyclic adenosine monophosphate (cAMP) is thought to be associated with inflammatory cell activity: high levels tend to decrease… 
Highly Cited
1998
Highly Cited
1998
We evaluated the airway activity of the novel phosphodiesterase type 4 inhibitor SB 207499 [Ariflo; c-4-cyano-4-(3-cyclopentyloxy… 
1997
1997
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept…